I lke this part it tells us alot without names Overview
We are looking to collaborate and/or partner with larger, more established, pharmaceutical companies who have interest in our potential target indications. Our preferred partner would have access to an experienced sales and marketing organization with an expertise in primary care markets on a national scale. We plan on developing compounds for FDA approval and commercialization, and would like to work with those who have the ability to market and distribute our products.
We are also interested in working with the numerous non-profit associations, societies, and government organizations who are focused and advocates for inflammatory and CNS disorders. Such collaborations can often lead to funds, grants, and relationships which will help bring therapeutics within specific indications to market.
For additional information, please contact us at BD@rockcreekpharma.com
In-licensing Strategy
Although we have extraordinary access to world class research, facilities and people, we are interested in complementing our technology and pipeline with externally sourced compounds that would be symbiotic with our current disease focus, either as stand alone or in co-formulation.
Strategic Partnering
We are interested in combining company strengths to reduce the risks inherent in drug development and maximize commercial opportunities.
Contact:
Ted Jenkins
Vice President, Corporate Strategy,
Development, Investor Relations
BD@rockcreekpharma.com
How Can We Work Together?
Name: *
Email: *
Asociations: *
Comments: *
Submit
HOME
AI
